What is the recommended treatment for allergic rhinitis, including appropriate medication choices and dosing?

Treatment of Allergic Rhinitis

For initial treatment of allergic rhinitis in patients aged 12 years or older, start with an intranasal corticosteroid (INCS) as monotherapy—this is the most effective single agent for controlling symptoms. 1

First-Line Treatment Algorithm

Monotherapy Approach (Preferred Initial Treatment)

Intranasal corticosteroids are the foundation of treatment and should be prescribed as first-line therapy for moderate to severe allergic rhinitis. 1 Common options include:

• Fluticasone propionate
• Fluticasone furoate
• Mometasone furoate

Do NOT routinely add an oral antihistamine to an intranasal corticosteroid for initial treatment—this combination provides no additional meaningful benefit over INCS alone. 1 This is a strong recommendation based on moderate-quality evidence showing that adding oral antihistamines does not improve symptom control or quality of life beyond what INCS achieves alone.

When to Consider Alternative Monotherapy

If patients prefer oral medication or cannot tolerate intranasal therapy, oral antihistamines are an option, though they are less effective than INCS. 2

For patients aged 15+ years, strongly recommend INCS over leukotriene receptor antagonists (like montelukast), as INCS provides superior nasal symptom reduction. 1 The exception: patients with concurrent mild persistent asthma may benefit from a leukotriene receptor antagonist for both conditions, though it remains suboptimal for rhinitis alone. 1

Second-Line Treatment: Combination Therapy

When Monotherapy Fails

For moderate to severe allergic rhinitis inadequately controlled by INCS alone, consider adding an intranasal antihistamine (such as azelastine) to create combination therapy. 1

The fixed combination of fluticasone propionate (200 mcg) plus azelastine (548 mcg) as a single spray shows:

• Greatest symptom reduction compared to either agent alone
• Baseline symptom scores of 18-19 out of 24 reduced by 5.3-5.7 points (versus 3.8-5.1 for INCS alone and 3.3-4.5 for intranasal antihistamine alone) 1
• Superior control of ocular symptoms 1

Important caveats for combination therapy:

• This is a weak recommendation due to concerns about added adverse effects and cost 1
• Common side effects include dysgeusia (altered taste, 2-13.5% of patients) and mild somnolence (0.4-1.1%) 1
• Most patients would choose this option when monotherapy fails, but many would not due to these factors 1

Real-World Evidence Insights

Real-world mobile health data from over 9,000 users demonstrates that:

• The fixed combination of intranasal antihistamine plus corticosteroid (MPAzeFlu) is superior to INCS alone in actual practice 2
• Patients using MPAzeFlu needed additional medications on only 30-35% of days, versus 45-60% of days for those using INCS alone 2
• This suggests better real-world symptom control with combination therapy 2

The most recent ARIA guidelines (2024-2025) now recommend INAH+INCS combination over either agent alone, representing an evolution in thinking based on this real-world evidence. 3

Treatment Hierarchy Summary

Ranked by effectiveness (based on real-world data):

1. Intranasal corticosteroid + intranasal antihistamine (fixed combination)
2. Intranasal corticosteroid alone
3. Intranasal antihistamine alone
4. Oral antihistamines (least effective) 2

Critical Pitfalls to Avoid

• Don't waste resources adding oral antihistamines to INCS—there is no benefit and this adds unnecessary cost and potential side effects 1
• Don't prescribe leukotriene receptor antagonists as first-line treatment unless there are specific contraindications to INCS or concurrent asthma 1
• Don't expect immediate perfect control—patients often self-titrate treatment based on symptom severity, and adherence is poor (less than 5% of patients maintain adherence over time) 2
• Don't overlook the option of prophylactic treatment for patients with predictable seasonal allergies—starting INCS before pollen season begins improves outcomes 4

Special Populations

For patients with concurrent asthma: Treating allergic rhinitis improves asthma outcomes, making aggressive rhinitis management particularly important in this population. 5

For adolescents (12+ years): All recommendations apply, though the fixed combination spray is particularly indicated for this age group with moderate to severe disease. 6